Asciminib may be a new treatment option for patients with chronic myeloid leukemia in the chronic phase (CML-CP). The following article features coverage from the American Society of Hematology 2020 ...
Tyrosine kinase inhibitors (TKIs) are first-line therapy for patients with chronic myeloid leukemia (CML). Successful response to these medications is associated with a life expectancy similar to that ...
Barriers to Cancer Care in Northern Tanzania: Patient and Health-System Predictors for Delayed Presentation We retrieved annual data on CML burden in 204 countries and regions from the Global Burden ...
Two posters presented at the European Hematology Association 2021 Virtual Congress evaluated tyrosine kinase inhibitor (TKI) selection in the front line and compared first-generation to ...
Terns Pharmaceuticals Inc., a NASH specialist based in San Francisco and Shanghai, has out-licensed the Greater China rights of its BCR-ABL inhibitor, TRN-000632, for treating chronic myeloid leukemia ...
Report of a chronic myeloid leukemia registry in a low-and middle-income setting.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results